OME Clinical Trials

4,614 recruitingLast updated: July 25, 2026

There are 4,614 actively recruiting ome clinical trials across 115 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


OME Trials at a Glance

4,614 actively recruiting trials for ome are listed on ClinicalTrialsFinder across 6 cities in 115 countries. The largest study group is Not Applicable with 1,669 trials, with the heaviest enrollment activity in Houston, Boston, and New York. Lead sponsors running ome studies include M.D. Anderson Cancer Center, Assistance Publique - Hôpitaux de Paris, and Riphah International University.

Treatments under study

About OME Clinical Trials

Looking for clinical trials for OME? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new OME trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about OME clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 4,614 trials

Recruiting
Phase 1Phase 2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

PregnancyMaternal ComplicationsPregnancy Complication+1 more
Jazz Pharmaceuticals50 enrolled2 locationsNCT06113237
Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled409 locationsNCT05256225
Recruiting
Not Applicable

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Arterial Occlusive DiseasesPainCardiovascular Diseases+12 more
Teleflex1,859 enrolled2 locationsNCT07258290
Recruiting
Phase 2

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals50 enrolled24 locationsNCT07354074
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Fanconi AnemiaInherited Bone Marrow Failure Syndrome
National Cancer Institute (NCI)200 enrolled1 locationNCT05687149
Recruiting
Not Applicable

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

Deep Venous ThrombosisVenous ThromboembolismPost Thrombotic Syndrome
Inari Medical300 enrolled64 locationsNCT05701917
Recruiting
Phase 1Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca602 enrolled60 locationsNCT05797168
Recruiting

Study of Proteus Syndrome and Related Congenital Disorders

Proteus SyndromePIK3CA Related Overgrowth Spectrum
National Human Genome Research Institute (NHGRI)1,500 enrolled1 locationNCT00001403
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled483 locationsNCT05564377
Recruiting
Phase 1

DBC-664 in Adult Patients With Solid Tumors

Urothelial CarcinomaLung AdenocarcinomaOvarian Adenocarcinoma+3 more
Duboce Biopharmaceuticals, Inc.210 enrolled3 locationsNCT07705035
Recruiting

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

Myelodysplastic Syndromes
National Cancer Institute (NCI)1,100 enrolled1 locationNCT05350748
Recruiting
Phase 2

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

LymphedemaFibrosisHead &Amp; Neck Cancer+1 more
M.D. Anderson Cancer Center250 enrolled1 locationNCT06912763
Recruiting
Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Colorectal, CancerGastric CancerEndometrial Cancer+4 more
MOMA Therapeutics132 enrolled15 locationsNCT06974110
Recruiting
Phase 2

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Adverse Pregnancy Outcome
Endeavor Health20 enrolled1 locationNCT06004674
Recruiting
Phase 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled296 locationsNCT07220083